TY - JOUR
T1 - Increasing incidence of melanoma among middle-aged adults
T2 - An epidemiologic study in olmsted county, minnesota
AU - Lowe, Garrett C.
AU - Saavedra, Alexandra
AU - Reed, Kurtis B.
AU - Velazquez, Ana I.
AU - Dronca, Roxana S.
AU - Markovic, Svetomir N.
AU - Lohse, Christine M.
AU - Brewer, Jerry D.
N1 - Funding Information:
Grant Support: This study was made possible by the Rochester Epidemiology Project (grant number R01-AG034676 ; Principal Investigators: Walter A. Rocca, MD, MPH, and Barbara P. Yawn, MD, MSc).
PY - 2014/1
Y1 - 2014/1
N2 - Objective: To identify changes in the incidence of cutaneous melanoma over time in the fastest-growing segment of the US populationdmiddle-aged adults. Patients and Methods: By using the Rochester Epidemiology Project resource, we identified patients aged 40 to 60 years who had a first lifetime diagnosis of melanoma between January 1, 1970, and December 31, 2009, in Olmsted County, Minnesota. The incidence of melanoma and overall and disease-specific survival rates were compared by age, sex, year of diagnosis, and stage of disease. Results: Between 1970 and 2009, age-and sex-adjusted incidence increased significantly over time (P<.001) from 7.9 to 60.0 per 100,000 person-years, with a 24-fold increase in women and a 4.5-fold increase in men. Although not significant (P.06), the incidence of melanoma increased with age. Overall and disease-specific survival improved over time, with hazard ratios of 0.94 (P<.001) and 0.93 (P<.001) for each 1-year increase in the year of diagnosis, respectively. Each 1-year increase in the age at diagnosis was associated with an increased risk of death from any cause (hazard ratio, 1.07; P.01) but was not significantly associated with disease-specific death (P.98). Sex was not significantly associated with death from any cause (P.81) or death from disease (P.23). No patient with malignant melanoma in situ died from disease. Patients with stage II, III, and IV disease were more than 14 times more likely to die from disease than were patients with stage 0 or I disease (P<.001). Conclusion: The incidence of cutaneous melanoma among middle-aged adults increased over the past 4 decades, especially in middle-aged women, whereas mortality decreased.
AB - Objective: To identify changes in the incidence of cutaneous melanoma over time in the fastest-growing segment of the US populationdmiddle-aged adults. Patients and Methods: By using the Rochester Epidemiology Project resource, we identified patients aged 40 to 60 years who had a first lifetime diagnosis of melanoma between January 1, 1970, and December 31, 2009, in Olmsted County, Minnesota. The incidence of melanoma and overall and disease-specific survival rates were compared by age, sex, year of diagnosis, and stage of disease. Results: Between 1970 and 2009, age-and sex-adjusted incidence increased significantly over time (P<.001) from 7.9 to 60.0 per 100,000 person-years, with a 24-fold increase in women and a 4.5-fold increase in men. Although not significant (P.06), the incidence of melanoma increased with age. Overall and disease-specific survival improved over time, with hazard ratios of 0.94 (P<.001) and 0.93 (P<.001) for each 1-year increase in the year of diagnosis, respectively. Each 1-year increase in the age at diagnosis was associated with an increased risk of death from any cause (hazard ratio, 1.07; P.01) but was not significantly associated with disease-specific death (P.98). Sex was not significantly associated with death from any cause (P.81) or death from disease (P.23). No patient with malignant melanoma in situ died from disease. Patients with stage II, III, and IV disease were more than 14 times more likely to die from disease than were patients with stage 0 or I disease (P<.001). Conclusion: The incidence of cutaneous melanoma among middle-aged adults increased over the past 4 decades, especially in middle-aged women, whereas mortality decreased.
UR - http://www.scopus.com/inward/record.url?scp=84893078134&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84893078134&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2013.09.014
DO - 10.1016/j.mayocp.2013.09.014
M3 - Article
AN - SCOPUS:84893078134
SN - 0025-6196
VL - 89
SP - 52
EP - 59
JO - Mayo Clinic proceedings
JF - Mayo Clinic proceedings
IS - 1
ER -